Loading
Today's T-cell-receptor drugs only work for people with one tissue type. Building versions for the other common types would roughly double who can be treated.
The idea is to build PRAME-directed ImmTAC T-cell engagers for patients who carry HLA-A*24:02 or HLA-A*11:01 rather than HLA-A*02:01, the tissue type that tebentafusp and brenetafusp currently require. The antigen and format stay the same and only the HLA context changes, in principle a solved engineering problem; Immunocore and others already have preclinical ImmTACs against PRAME on HLA-A*24 and A*11, common in East Asian populations. The hypothesis is that these agents match the activity and safety of the A*02 drug, roughly doubling the number of people who could be treated. The test is a phase 1 dose escalation in HLA-A*24:02-positive melanoma in Japan and Korea mirroring IMCgp100-202; the evidence is preclinical and the idea bears on HLA-A*02:01 restriction.
A second publication from the IMCgp100-202 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT03070392 with the most citations, so it is the natural first reading for anyone following the IMCgp100-202 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
One of the most cited reviews Europe PMC returns for Tebentafusp in Melanoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma, Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma, Tebentafusp, T-cell engagers (bispecific).
Shares HLA-A*02:01 restriction, Brenetafusp, PRAME, Tebentafusp.
Shares Brenetafusp, PRAME, T-cell engagers (bispecific), Melanoma.
Shares Tebentafusp, TCR-T cell therapy, T-cell engagers (bispecific), Melanoma.
Shares Brenetafusp, Tebentafusp, T-cell engagers (bispecific).
Shares Brenetafusp, PRAME, Tebentafusp, Melanoma.
Shares Brenetafusp, PRAME, Tebentafusp, TCR-T cell therapy.
Shares Tebentafusp, TCR-T cell therapy, T-cell engagers (bispecific), Melanoma.